Jérôme Honnorat

Active 1995–2026

216
Papers
27,651
Citations
93
h-index
195
i10-index

Citations

Citations per year for Jérôme Honnorat1982: 1 citations1986: 2 citations1990: 1 citations1997: 5 citations1998: 4 citations1999: 9 citations2000: 11 citations2001: 17 citations2002: 27 citations2003: 44 citations2004: 56 citations2005: 54 citations2006: 77 citations2007: 98 citations2008: 76 citations2009: 76 citations2010: 79 citations2011: 105 citations2012: 137 citations2013: 127 citations2014: 139 citations2015: 141 citations2016: 154 citations2017: 251 citations2018: 219 citations2019: 759 citations2020: 895 citations2021: 916 citations2022: 862 citations2023: 616 citations2024: 1,228 citations2025: 489 citations2026: 6 citations1983–1985: no citations, so these years are not shown1987–1989: no citations, so these years are not shown1991–1996: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,882 citing papers, 23.1% of this breakdownChina: 695 citing papers, 8.5% of this breakdownGermany: 649 citing papers, 8% of this breakdownFrance: 634 citing papers, 7.8% of this breakdownUnited Kingdom: 542 citing papers, 6.7% of this breakdownItaly: 420 citing papers, 5.2% of this breakdownSpain: 343 citing papers, 4.2% of this breakdownNetherlands: 280 citing papers, 3.4% of this breakdownCanada: 254 citing papers, 3.1% of this breakdownJapan: 241 citing papers, 3% of this breakdownSwitzerland: 232 citing papers, 2.9% of this breakdownAustralia: 205 citing papers, 2.5% of this breakdown
0%23.1%Other 21.6%

Fields

  • Medicine75%
  • Neuroscience11.4%
  • Biochemistry, Genetics and Molecular Biology8.1%
  • Immunology and Microbiology2.1%
  • Engineering1.2%
  • Mathematics0.7%
  • Other1.5%

Topics

  • Autoimmune Neurological Disorders and Treatments10.9%
  • Glioma Diagnosis and Treatment8.1%
  • Peripheral Neuropathies and Disorders4.6%
  • Brain Metastases and Treatment3.2%
  • Multiple Sclerosis Research Studies2.7%
  • Cancer Immunotherapy and Biomarkers2.1%
  • Other68.4%

Coauthors

All papers

Open in search
  1. A clinical approach to diagnosis of autoimmune encephalitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2016 cited by 4,396

  2. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 cited by 501

  3. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2015 cited by 1,226

  4. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2021 cited by 708

  5. Register allocation: A program-algebraic approach

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey N. Bruce, Rees Cosgrove, Nina Paleologous, Yoram Palti, Philip H. Gutin - European Journal of Cancer 2001 cited by 847

  6. Neurologic Adverse Events of Immune Checkpoint Inhibitors

    Authors: , , , , , , - Neurology 2021 cited by 250

  7. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes

    Authors: , , , , , , , , - The Lancet Neurology 2023 cited by 120

  8. Glial Fibrillary Acidic Protein Autoimmunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eve Chanson, Amélie Leblanc, E. Morvan, Daniela Andriuta, Philippe Diraison, Gabriel Mirebeau, Céline Derollez, Veronique Bourg, Q. Bodard, Clementine Fort, Irina Grigorashvili-Coin, Guillaume Rieul, Daniela Molinier-Tiganas, Mickaël Bonnan, Thierry Tchoumi, Jérôme Honnorat, Romain Marignier - Neurology 2021 cited by 149

  9. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Brain Communications 2023 cited by 83

  10. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors

    Authors: , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2019 cited by 190

  11. Clinical and genetic keys to cerebellar ataxia due to FGF14 GAA expansions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anna Castrioto, Silvia Fenu, Aurélie Méneret, Frédéric Bourdain, Marion Wandzel, Virginie Roth, Céline Bonnet, Florence Riant, Giovanni Stévanin, Sandrine Noël, Anne‐Laure Fauret‐Amsellem, Melanie Bahlo, Paul J. Lockhart, Bernard Brais, Mathilde Renaud, Alexis Brice, Alexandra Dürr - EBioMedicine 2023 cited by 57

  12. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 192

  13. Central nervous system complications associated with immune checkpoint inhibitors

    Authors: , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2020 cited by 150

  14. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France

    Authors: , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2020 cited by 130

  15. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features

    Authors: , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2020 cited by 100

  16. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis

    Authors: , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2021 cited by 100

  17. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors

    Authors: , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 63

  18. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force

    Authors: , , , , , , , , , , , , - European Journal of Neurology 2010 cited by 518

  19. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis

    Authors: , , , , , , , , - Brain 2012 cited by 330

  20. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes

    Authors: , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2020 cited by 126

  21. VEGF counteracts amyloid-β-induced synaptic dysfunction

    Authors: , , , , , , , , , , - Cell Reports 2021 cited by 48

  22. Surface dynamics of GluN2B‐NMDA receptors controls plasticity of maturing glutamate synapses

    Authors: , , , , , , , , , , - The EMBO Journal 2014 cited by 128

  23. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

    Authors: , , , , , , , , , , , , , , , , , , , - Acta Neuropathologica 2018 cited by 117

  24. Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olivier Lambotte, Jean‐Marie Michot - Journal for ImmunoTherapy of Cancer 2019 cited by 106